Last reviewed · How we verify
GSK2894512 Cream
At a glance
| Generic name | GSK2894512 Cream |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Folliculitis
- Headache
- Dermatitis contact
- Nasopharyngitis
- Upper respiratory
- Acne
- Dermatitis atopic
- Dermatitis allergic
- Impetigo
- Conjunctivitis
- Sinusitis
- Body tinea
Key clinical trials
- GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis (PHASE3)
- A Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of GSK2894512 in Healthy Adult Subjects (PHASE1)
- A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD) (PHASE2)
- A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis (PHASE2)
- Skin Irritation Study of GSK2894512 Cream (PHASE1)
- A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects (PHASE1)
- Pharmacokinetic Study of Topical GSK2894512 Cream (PHASE1)
- A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK2894512 Cream CI brief — competitive landscape report
- GSK2894512 Cream updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI